{"id":524231,"date":"2021-08-05T09:33:15","date_gmt":"2021-08-05T13:33:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/"},"modified":"2021-08-05T09:33:15","modified_gmt":"2021-08-05T13:33:15","slug":"pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/","title":{"rendered":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference"},"content":{"rendered":"

<\/p>\n

PAVmed<\/b>to Present at the 41st Annual Canaccord Genuity Growth Conference<\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ<\/b>) (the \u201cCompany\u201d or \u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT.\n<\/p>\n

\nTo access the live webcast of the presentation, please click here<\/a>. A replay will be available following the presentation and can be accessed in the Investor Relations<\/a> section of the PAVmed website.\n<\/p>\n

About PAVmed <\/b><\/p>\n

\nPAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer \u2013 the EsoGuard\u00ae<\/sup> Esophageal DNA Test and EsoCheck\u00ae<\/sup> Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure\u2122 Esophageal Ablation Device with Caldus\u2122 Technology. Its Minimally Invasive Interventions division markets its CarpX\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Other divisions include Infusion Therapy (PortIO\u2122 Implantable Intraosseous Vascular Access Device and NextFlo\u2122 Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com<\/a>, follow us on Twitter<\/a>, connect with us on LinkedIn<\/a>, and watch our videos on YouTube<\/a>. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com<\/a>, follow Lucid on Twitter<\/a>, and connect with Lucid on LinkedIn<\/a>. For detailed information on EsoGuard, please visit www.EsoGuard.com<\/a> and follow us on Twitter<\/a>, Facebook<\/a> and Instagram<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed\u2019s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed\u2019s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed\u2019s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed\u2019s preclinical studies; whether and when PAVmed\u2019s products are cleared by regulatory authorities; market acceptance of PAVmed\u2019s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company\u2019s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed\u2019s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed\u2019s future operations, see Part I, Item IA, \u201cRisk Factors,\u201d in PAVmed\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \u201cRisk Factors\u201d in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210805005649\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/span>
Mike Havrilla
\n
Director of Investor Relations
\n
(814) 241-4138
\n
JMH@PAVmed.com
\n<\/a><\/p>\n

Media
\n<\/span>
Katie Gallagher \/ Kristi Bruno
\n
LaVoieHealthScience
\n
(617) 792-3937 \/ (617) 865-3940
\n
PAVmed@lavoiehealthscience.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Oncology Medical Devices Health Finance Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the \u201cCompany\u201d or \u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT. To access the live webcast of the presentation, please click here. A replay will be available following the presentation and can be accessed in the Investor Relations section of the PAVmed website. About PAVmed PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum … <\/p>\n

Continue reading “PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-524231","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the \u201cCompany\u201d or \u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT. To access the live webcast of the presentation, please click here. A replay will be available following the presentation and can be accessed in the Investor Relations section of the PAVmed website. About PAVmed PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum … Continue reading "PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T13:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference\",\"datePublished\":\"2021-08-05T13:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/\"},\"wordCount\":782,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/\",\"name\":\"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-05T13:33:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk","og_description":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the \u201cCompany\u201d or \u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT. To access the live webcast of the presentation, please click here. A replay will be available following the presentation and can be accessed in the Investor Relations section of the PAVmed website. About PAVmed PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum … Continue reading \"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T13:33:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference","datePublished":"2021-08-05T13:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/"},"wordCount":782,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/","name":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-05T13:33:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210805005649r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmedto-present-at-the-41st-annual-canaccord-genuity-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PAVmedto Present at the 41st Annual Canaccord Genuity Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=524231"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524231\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=524231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=524231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=524231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}